DNA METHYLATION BIOMARKERS FOR CANCER DIAGNOSING AND TREATMENT
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 11, 2022
app pub date -
Jun 5, 2020
filing date -
Jun 14, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Cancer is the second most common cause of death worldwide, identification of cancer-specific DNA methylation events released by tumors into blood can be used for cost-effective, minimally invasive diagnostics and monitoring of cancer. The present invention clinically tested a set of ten DNA methylation specific qPCR amplicons, designed to detect most common human carcinoma types, in cell free DNA extracted from plasma fraction of blood samples from healthy controls and non-small cell lung cancer (NSCLC) cases. The DNA methylation biomarkers distinguish lung cancer cases from controls with high sensitivity and specificity (AUC=0.956), and furthermore, the signal from the markers depends on the tumor size and decreases after surgical resection of lung tumors. These observations indicate clinical value of these DNA methylation biomarkers for minimally invasive diagnostics and monitoring of NSCLC. It is predicted that these DNA methylation biomarkers will detect additional carcinoma types as well.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully